Colistin-glycopeptide combinations against multidrug-resistant Acinetobacter baumannii in a mouse model of pneumonia

Related Experiment Video

Updated: Jan 23, 2026

In Vivo Investigation of Antimicrobial Blue Light Therapy for Multidrug-resistant Acinetobacter baumannii Burn Infections Using Bioluminescence Imaging
09:29

In Vivo Investigation of Antimicrobial Blue Light Therapy for Multidrug-resistant Acinetobacter baumannii Burn Infections Using Bioluminescence Imaging

Published on: April 28, 2017

9.9K

Diane Sanderink1,2, Viviane Cassisa3, Rachel Chenouard1,3

  • 1CRCINA, Inserm, Université de Nantes, Université d'Angers, Angers, 44200 Nantes, France.

Future Microbiology
|June 8, 2019
PubMed

Insights

The colistin-teicoplanin combination significantly improved survival in a mouse model of multidrug-resistant Acinetobacter baumannii pneumonia. This combination shows promise for treating difficult Acinetobacter baumannii infections.

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Pharmacology

Background:

  • Multidrug-resistant Acinetobacter baumannii poses a significant threat.
  • Limited treatment options exist for carbapenem-resistant strains.
  • Colistin is often a last resort, but resistance is emerging.

Purpose of the Study:

  • To evaluate the efficacy of colistin combined with glycopeptides against multidrug-resistant Acinetobacter baumannii.
  • To assess the combination therapy in an in vitro and in vivo model.

Main Methods:

  • In vitro methods included Etest, checkerboard, and kill-time assays.
  • An in vivo study utilized a mouse model of carbapenem-resistant Acinetobacter baumannii pneumonia.
  • Survival rates were compared between treatment groups and controls.

Main Results:

  • The colistin-teicoplanin combination increased survival by 74% in the mouse model compared to saline or colistin alone (p=0.06).
  • The colistin-vancomycin combination showed no significant difference in efficacy compared to saline or colistin alone.
  • In vitro susceptibility testing informed the in vivo experiments.

Conclusions:

  • The colistin-teicoplanin combination demonstrates potential therapeutic value for multidrug-resistant Acinetobacter baumannii pneumonia.
  • Further studies are warranted to confirm these preliminary findings.
  • This combination may offer a solution for challenging clinical cases of Acinetobacter baumannii infections.
Keywords:
antimicrobial combinationscolistinexperimental infectionsglycopeptidesmultidrug resistancepneumoniateicoplaninvancomycin

More Related Videos

The Application of Open Searching-based Approaches for the Identification of Acinetobacter baumannii O-linked Glycopeptides08:37

The Application of Open Searching-based Approaches for the Identification of Acinetobacter baumannii O-linked Glycopeptides

Published on: November 2, 2021

2.5K
A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

15.2K

Related Concept Videos

Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
788
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
2.7K
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
783
Resistivity01:22

Resistivity

When a voltage is applied to a conductor, an electrical field is generated, and charges in the conductor feel the force due to the electrical field. The current density that results depends on the electrical field and the properties of the material. In some materials, including metals at a given temperature, the current density is approximately proportional to the electrical field. In these cases, the current density can be modeled as:
4.4K
Resistance01:19

Resistance

When a current moves through any conductor, the conductor causes some level of difficulty for the current to flow. The measure of that difficulty is known as the resistance of the material and is represented by R. Every material has its own resistance. In the case of conductors, heat is emitted whenever a current passes through them. Resistance depends on the resistivity of the material. Resistivity is a characteristic of the material used to fabricate electrical components, whereas the...
5.7K
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
3.5K